Menu

Events on 27 September 2023

CONGRESS 2023 - Your career in Clinical Biochemistry: IBMS qualifications and the role of the Advisory Panel (Wednesday)

27/09/2023
Your career in Clinical Biochemistry: IBMS qualifications and the role of the Advisory Panel

CONGRESS 2023 - The metabolic role of Vitamin B12

27/09/2023
Delegates will understand:

The pathophysiological aspects of Vitamin B12.
The role of the laboratory in the diagnosis of Vitamin B12 deficiency.

CONGRESS 2023 - 2pm The metabolic role of Vitamin B12 Clinical Chemistry 2.30pm Lipid disorders Clinical Chemistry Lipid disorders

27/09/2023
This presentation will provide an update Update to the clinical use of lipids and the laboratory role in lipid disorders.

CONGRESS 2023 - Molar pregnancy and gestational trophoblastic disease – why the hCG assay matters

27/09/2023
In this presentation, Imran Jabbar, will delve into the crucial topic of measuring human chorionic gonadotrophin (hCG) in gestational trophoblastic disease (GTD). With a focus on trophoblastic tumours, Imran will explore the significance of hCG as a diagnostic and monitoring tool in GTD. The presentation will cover the principles behind hCG measurement techniques, including immunoassays and molecular methods.

Imran will highlight the challenges and advancements in accurately quantifying hCG levels, and discuss their clinical implications. Attendees will gain insights into the role of hCG measurement in early detection, disease monitoring, and prognostic evaluation, ultimately contributing to improved patient outcomes in GTD management.

CONGRESS 2023 - Reporting direct to the patient

27/09/2023
In recent years, healthcare policy has been moving towards the concept of patients being able to receive their pathology test results directly, it is likely that pathology providers may need to consider the communication of some laboratory test results directly to patients.

This is a very different group of people to what pathology providers are used to. Expansion of concepts such as reference intervals and what is significant need to be explored in the context of a more general audience.

CONGRESS 2023 - Head & Neck Clinic – Sonographer’s perspective

27/09/2023
Head and Neck cancers account for approximately 3% of new cancer incidence in the United Kingdom (UK). The use of ultrasound guided fine needle aspirations within head and neck ultrasound, has become a vital resource for cancer diagnosis. Historically, it was common for head and neck patients requiring a fine needle aspiration, to have an insufficient tissue sample from their initial examination, leading to patient re-call for repeat investigation. Subsequently, this negatively impacted upon the patient pathway by delaying cancer diagnosis and treatment.

The utilisation of Rapid on-site Evaluation (ROSE) has proven to transform the diagnostic pathway by negating the need for repeat examinations and therefore improving the rate at which patients are diagnosed and treated.

This presentation focuses on the achievements that have been accomplished through great collaborative working between radiology and cytology within head and neck and the consequent patient benefits. It includes a summary of how the ROSE service has grown at Royal Cornwall Hospital to include the Cornwall ROSE research pilot and the values this has brought to the population.

Case studies will be included as examples of where ROSE has been paramount to a swift diagnosis.

Additionally, the advantages and disadvantages of working with ROSE will be discussed from a sonographer's viewpoint, highlighting the potential pitfalls.



References

1. Head and neck cancers statistics | Cancer Research UK [Internet]. [cited 2023 May 26]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-Zero

2. Breeze J, Poller DN, Gibson D, Tilley EA, Cooke L, Soar E, et al. Rapid on-site assessment of specimens by biomedical scientists improves the quality of head and neck fine needle aspiration cytology. Cytopathology. 2013 Oct;n/a-n/a.

3. Medina Chamorro FM, Calle JA, Stein JE, Merchancano L, Mendoza Briñez AM, Pulido Wilches AA. Experience of the Implementation of Rapid On-Site Evaluation in Ultrasound-Guided Fine-Needle Aspiration Biopsy of Thyroid Nodules. Curr Probl Diagn Radiol. 2018 Jul;47(4):220–4.

4. Aly AK, Ali MA, Sharma A, Gubbels MA, Zhao X, Ahmed A, et al. Rapid On-site Evaluation (ROSE) for Fine Needle Aspiration of Thyroid: Is It Helpful? SciMed J. 2021 Mar 1;3(1):1–7.

CONGRESS 2023 - Pathology of Head & Neck – Histology & Cytology

27/09/2023
The aim for this session is to carry on with the patient’s journey to final diagnosis. This presentation will discuss how the valuable material obtained from ROSE clinics are utilised in making a diagnosis and provide prognostic/treatment related information.

With the use of a number of examples, this presentation will illustrate how cytology impacts on patient’s management pathway, and how a standardised reporting system could be useful in unifying diagnostic pathways and performing future work on audit and quality improvement.

Finally, the strengths and limitations of head and neck cytology from the perceptive of a histo/cytopathologist will be discussed

CONGRESS 2023 - Specialist portfolios: Updated, flexible and achievable

27/09/2023
Specialist portfolios: Updated, flexible and achievable

CONGRESS 2023 - New ROSE specialist module

27/09/2023
The requirement of extensive and complex testing on cytology samples is widely and routinely recognised. ROSE performed by scientists in the clinical setting provides a standardised, clinically effective, reproducible methodology for a variety of anatomical sites, some of which cytology is the only modality for sampling.

Real-time adequacy assessment eliminates the need for more invasive or repeat procedures by ensuring sufficient cell yield is obtained to conduct all the tests required for ancillary and molecular testing. This streamlines the patient pathway by reducing the referral to treatment time and reduces waiting list pressures, resulting in cost reduction for healthcare trusts and improved patient care and outcomes.

The presentation will explore the new IBMS ROSE qualification with the aim to inspire scientists to become skilled in ROSE.

CONGRESS 2023 - Changing and expanding roles in Cellular Pathology

27/09/2023
Changing and expanding roles in Cellular Pathology
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11